Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 369 M
EBIT 2017 -38,1 M
Net income 2017 -74,5 M
Finance 2017 109 M
Yield 2017 -
Sales 2018 448 M
EBIT 2018 -47,2 M
Net income 2018 -78,6 M
Finance 2018 125 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 12,8x
EV / Sales2018 10,5x
Capitalization 4 824 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery.It operates its business through the Ionis Core and Akea Therapeutics segments.The Ionis Core segment involves a a novel drug discovery platform generate a broad pipeline of drugs.The Akea... 
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
03/27 IONIS PHARMACEUTICALS,INC. (NASDAQ : IONS) Files An 8-K Other Events
03/27 IONIS PHARMACEUTICALS : Akcea Therapeutics Files Registration Statement for Prop..
03/27 IONIS PHARMACEUTICALS INC : Other Events (form 8-K)
03/23 IONIS PHARMACEUTICALS : Reports from Ionis Pharmaceuticals Highlight Recent Find..
03/17 IONIS PHARMACEUTICALS : ` Latest Attempt To Weaponize Antisense Against Cancer
03/16 IONIS PHARMACEUTICALS : Reports from Ionis Pharmaceuticals Advance Knowledge in ..
03/08 Goldberg Law PC Announces an Investigation of Ionis Pharmaceuticals Inc. and ..
03/06 Levi & Korsinsky, LLP Announces the Commencement of an Investigation of Ionis..
03/06 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ionis Pharmaceu..
03/06 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharma..
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 46,7 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & Senior VP-Finance
Joseph H. Wender Independent Director
Frederick T. Muto Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%4 824
INCYTE CORPORATION39.26%28 461
QUINTILES IMS HOLDINGS..2.55%18 400
LONZA GROUP AG3.40%10 646
CELLTRION, INC.--.--%9 851
SEATTLE GENETICS, INC.20.69%9 075
More Results